Author

D. Barnes

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. B. HASSAN· 1 shared B. Feierbach· 1 shared C. Bühnemann· 1 shared C. H. Tay· 1 shared C. J. Imianowski· 1 shared C. Snyder· 1 shared D. Tam· 1 shared E. Carter· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. B. HASSAN

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Smad4 and TGF-β1 dependent gene expression biomarkers in conditional intestinal adenoma, organoids and colorectal cancer.

M. Surakhy, J. Matheson, D. Barnes, E. Carter, J. Hughes, C. Bühnemann, S. Sanegre, H. Morreau, P. Metz, C. J. Imianowski, A. B. HASSAN

The paper identifies Smad4 and TGF-β1 dependent gene expression biomarkers in intestinal adenomas and colorectal cancer using murine models and RNA sequencing.

bioRxiv · Mar 15, 2024 · PreprintCancer Biology

Characterization of a KDM5 Small Molecule Inhibitor with Antiviral Activity against Hepatitis B Virus

U. Schmitz, S. A. Gilmore, D. Tam, T. L. Cheung, C. Snyder, J. Farand, R. Dick, M. Matles, J. Y. Feng, R. Ramirez, L. Li, H. Yu, Y. Xu, D. Barnes, G. Czerwieniec, , B. Feierbach

This study identifies a KDM5 inhibitor with anti-HBV activity in vitro but not in vivo, highlighting challenges in translating epigenetic therapies to viral infections.

bioRxiv · Jun 27, 2022 · PreprintPharmacology & Toxicology